The U.S. Food and Drug Administration (FDA) has approved the first generic version of Climara Pro, a combination hormone therapy patch designed for women with an intact uterus. The approval introduces another treatment option for managing menopause-related symptoms and helping prevent postmenopausal osteoporosis.
The generic patch, containing estradiol and levonorgestrel, is therapeutically equivalent to the branded medication and is applied once a week. According to the FDA, it is indicated for treating moderate to severe vasomotor symptoms associated with menopause and preventing postmenopausal osteoporosis.
Unlike estrogen-only patches, this combination treatment includes both estrogen and a progestogen. The progestogen component helps reduce the risk of endometrial hyperplasia associated with estrogen use alone, making the therapy specifically suitable for its approved use in women with an intact uterus.
The FDA said the approval supports efforts to improve access to affordable medicines. Generic medications can increase market competition and potentially reduce treatment costs, although the availability and price of the newly approved patch will depend on the manufacturer and market conditions.
Zydus Pharmaceuticals (USA) Inc. received approval to market the generic medication. Patients and healthcare professionals should contact the manufacturer for information about availability.
The FDA also highlighted important safety considerations. The medication is not appropriate for everyone, including people with certain histories of breast cancer, blood clots, liver disease or unexplained abnormal genital bleeding. Common adverse reactions include application-site reactions, vaginal bleeding, breast pain, headache and back pain.
Women considering hormone therapy should consult a qualified healthcare professional to assess potential benefits, risks and individual treatment needs.
